{
    "clinical_study": {
        "@rank": "107829", 
        "brief_summary": {
            "textblock": "RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer\n      cells.\n\n      PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who\n      have metastatic kidney cancer."
        }, 
        "brief_title": "Interleukin-2 in Treating Patients With Metastatic Kidney Cancer", 
        "completion_date": {
            "#text": "July 2007", 
            "@type": "Actual"
        }, 
        "condition": "Kidney Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the overall response rate, complete and partial response rates, and duration\n           of response in patients with metastatic renal cell carcinoma treated with low-dose\n           interleukin-2.\n\n        -  Determine the overall survival, one-year progression-free survival, and two-year\n           progression-free survival in patients treated with this regimen.\n\n        -  Determine the incidence of adverse events in these patients.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive low-dose interleukin-2 subcutaneously 5 days a week for 6 weeks. Courses\n      repeat every 9 weeks for at least 2 courses in the absence of disease progression or\n      unacceptable toxicity.\n\n      Patients are followed every 3 months for 2 years.\n\n      PROJECTED ACCRUAL: A total of 464 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven metastatic renal cell carcinoma\n\n               -  Clear cell\n\n               -  Papillary\n\n               -  Sarcomatoid\n\n               -  Mixed\n\n          -  Measurable or evaluable disease\n\n          -  Evidence of disease following surgical resection of metastases\n\n          -  No CNS disease\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Hemoglobin at least 10 g/dL\n\n          -  WBC at least 4,000/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Creatinine no greater than 1.8 mg/dL\n\n        Cardiovascular:\n\n          -  No New York Heart Association class III or IV heart disease\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception (barrier plus 1 other method)\n\n          -  Thyroid-stimulating hormone normal\n\n          -  No known hypersensitivity or allergy to components of recombinant human interleukin-2\n\n          -  No known autoimmune disease (e.g., Crohn's disease)\n\n          -  No other concurrent medical condition that would preclude study\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior recombinant human interleukin-2\n\n          -  No concurrent interferon alfa\n\n        Chemotherapy:\n\n          -  No concurrent cytoxic chemotherapy\n\n        Endocrine therapy:\n\n          -  No concurrent hormonal therapy (e.g., medroxyprogesterone) other than estrogen\n             replacement therapy\n\n          -  No concurrent prophylactic glucocorticoids (replacement doses and topical use\n             allowed)\n\n          -  No concurrent systemic corticosteroids\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy\n\n          -  No prior radiotherapy to index lesion\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  Prior surgery for renal cell carcinoma allowed\n\n        Other:\n\n          -  No prior systemic therapy for renal cell carcinoma\n\n          -  At least 4 weeks since prior investigational drugs\n\n          -  No other concurrent investigational drugs or participation in another clinical study\n\n          -  No concurrent iodinated radiocontrast dye\n\n          -  No concurrent drugs for another indication that has purported activity in treatment\n             of neoplasia (e.g., thalidomide)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "December 6, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006864", 
            "org_study_id": "CHIR1899", 
            "secondary_id": [
                "CWRU-CHIR-1899", 
                "CHIR-MA-99-01", 
                "CWRU-010002", 
                "NCI-G00-1875"
            ]
        }, 
        "intervention": {
            "intervention_name": "aldesleukin", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Aldesleukin", 
                "Interleukin-2"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage IV renal cell cancer", 
            "recurrent renal cell cancer", 
            "clear cell renal cell carcinoma"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CWRU-CHIR-1899"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Torrington", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06790"
                    }, 
                    "name": "Northwestern Connecticut Oncology-Hematology Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106-5065"
                    }, 
                    "name": "Ireland Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin", 
        "overall_official": {
            "affiliation": "University Hospitals Seidman Cancer Center", 
            "last_name": "Cindy Connell, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2007", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006864"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Case Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Chiron Corporation", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Case Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }, 
    "geocoordinates": {
        "Ireland Cancer Center": "41.499 -81.695", 
        "Northwestern Connecticut Oncology-Hematology Associates": "41.801 -73.121"
    }
}